IRadimed Sees Q3 EPS $0.38-$0.41 Vs $0.37 Est.; Revenue $18M-$18.2M Vs $17.7M Est. Reiterates FY24 EPS Of $1.52-$1.62 Vs $1.53 Est.; Revenue $72M-$74M Vs $72.29M Est.
Portfolio Pulse from Benzinga Newsdesk
IRadimed Corporation (IRMD) has announced its Q3 2024 earnings per share (EPS) guidance of $0.38-$0.41, surpassing the estimated $0.37. The company also expects Q3 revenue of $18M-$18.2M, above the estimated $17.7M. For FY24, IRadimed reiterates its EPS guidance of $1.52-$1.62 and revenue guidance of $72M-$74M.
August 01, 2024 | 12:47 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
IRadimed Corporation (IRMD) has raised its Q3 2024 EPS guidance to $0.38-$0.41, exceeding the estimated $0.37. The company also anticipates Q3 revenue of $18M-$18.2M, above the estimated $17.7M. Additionally, IRadimed has reiterated its FY24 EPS guidance of $1.52-$1.62 and revenue guidance of $72M-$74M.
IRadimed's raised Q3 EPS and revenue guidance, along with the reiteration of its FY24 guidance, indicates strong financial performance and positive market sentiment. This is likely to boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100